ADMA ADMA Biologics Inc

4.26
-0.28  -6%
Previous Close 4.54
Open 4.54
Price To Book 6.98
Market Cap 252,696,192
Shares 59,318,355
Volume 1,071,286
Short Ratio
Av. Daily Volume 796,487
Stock charts supplied by TradingView

NewsSee all news

  1. ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2019 Revenues and Provides 2020 Strategic Outlook

    Achieved Fourth Quarter 2019 Preliminary Unaudited Total Revenues of $11.9 Million, a 193% Increase Over Fourth Quarter 2018 Full Year 2019 Preliminary Unaudited Total Revenues of $29.2 Million, a 72% Increase Over Full

  2. ADMA Biologics Enters Into a Manufacturing and Supply Agreement to Produce and Sell Plasma-Derived Intermediate Fractions

    Agreement is Expected to Add $5-10 Million in Annual Revenues for 2020 and 2021, and $10-20 Million Per Year for 2022 Through 2024 RAMSEY, N.J. and BOCA RATON, Fla., Jan. 07, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics,

  3. ADMA Biologics Added to NASDAQ Biotechnology Index

    RAMSEY, N.J. and BOCA RATON, Fla., Dec. 17, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a commercial biopharmaceutical company dedicated to manufacturing, marketing and

  4. ADMA Biologics to Present at Jefferies 2019 London Healthcare Conference

    RAMSEY, N.J. and BOCA RATON, Fla., Nov. 13, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a commercial biopharmaceutical company dedicated to manufacturing, marketing and

  5. ADMA Biologics Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress

    Third Quarter Total Revenues of $7.2 Million, a 71% Increase Year Over Year Commercial Rollouts for Immunoglobulins (IVIG) Off to an Encouraging Start RAMSEY, N.J. and BOCA RATON, Fla., Nov. 06, 2019 (GLOBE NEWSWIRE)

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA Approval announced April 1, 2019.
RI-002
Primary Immune Deficiency Diseases
Response to Complete Response Letter submitted January 7, 2019.
BIVIGAM
Primary humoral immunodeficiency

Latest News

  1. ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2019 Revenues and Provides 2020 Strategic Outlook

    Achieved Fourth Quarter 2019 Preliminary Unaudited Total Revenues of $11.9 Million, a 193% Increase Over Fourth Quarter 2018 Full Year 2019 Preliminary Unaudited Total Revenues of $29.2 Million, a 72% Increase Over Full

  2. ADMA Biologics Enters Into a Manufacturing and Supply Agreement to Produce and Sell Plasma-Derived Intermediate Fractions

    Agreement is Expected to Add $5-10 Million in Annual Revenues for 2020 and 2021, and $10-20 Million Per Year for 2022 Through 2024 RAMSEY, N.J. and BOCA RATON, Fla., Jan. 07, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics,

  3. ADMA Biologics Added to NASDAQ Biotechnology Index

    RAMSEY, N.J. and BOCA RATON, Fla., Dec. 17, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a commercial biopharmaceutical company dedicated to manufacturing, marketing and

  4. ADMA Biologics to Present at Jefferies 2019 London Healthcare Conference

    RAMSEY, N.J. and BOCA RATON, Fla., Nov. 13, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a commercial biopharmaceutical company dedicated to manufacturing, marketing and

  5. ADMA Biologics Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress

    Third Quarter Total Revenues of $7.2 Million, a 71% Increase Year Over Year Commercial Rollouts for Immunoglobulins (IVIG) Off to an Encouraging Start RAMSEY, N.J. and BOCA RATON, Fla., Nov. 06, 2019 (GLOBE NEWSWIRE)

  6. ADMA Biologics Announces Acceptance to the Plasma Protein Therapeutics Association

    RAMSEY, N.J. and BOCA RATON, Fla., Nov. 04, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a commercial biopharmaceutical company dedicated to manufacturing, marketing and

  7. ADMA Biologics Announces Publication of an Article Describing the Manufacturing Process Optimization for its Commercial Products BIVIGAM® and ASCENIV™ in the Peer Reviewed Journal Immunotherapy

    RAMSEY, N.J. and BOCA RATON, Fla., Oct. 17, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a commercial biopharmaceutical company dedicated to manufacturing, marketing and

  8. ADMA Biologics Announces Data Presented at IDWeek 2019

    RAMSEY, N.J. and BOCA RATON, Fla., Oct. 07, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin

  9. ADMA Biologics Announces Poster Presentation at IDWeek 2019

    RAMSEY, N.J. and BOCA RATON, Fla., Oct. 03, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin

  10. ADMA Biologics to Present at 2019 Cantor Global Healthcare Conference

    RAMSEY, N.J. and BOCA RATON, Fla., Sept. 23, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin

  11. ADMA Biologics Announces Commercial Relaunch and its First Commercial Sales of BIVIGAM®

    RAMSEY, N.J. and BOCA RATON, Fla., Aug. 22, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin